Online inquiry

IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7847MR)

This product GTTS-WQ7847MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets RTN4 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001321859.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57142
UniProt ID Q9NQC3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7847MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3849MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-054
GTTS-WQ5099MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ12923MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ11201MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ5755MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ14865MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ7316MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ3534MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BART
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW